Martin Edwards, Chairman

Martin is Senior Partner at Novo Ventures, Novo A/S, which he joined in 2003, and a member of the board of directors of Funxional Therapeutics Ltd. and Tarsa Therapeutics, Inc.

From 1998-2003 he was CEO of UK-based stem cell company ReNeuron Group plc, and between 1994-1998 he was Corporate VP and Head of Drug Development for Novo Nordisk A/S where he was responsible for all aspects of pre-clinical and clinical drug development.

Previously, Martin worked in the USA first as VP Pharmacology and Medical Affairs of ZymoGenetics, Inc. in Seattle and then as Senior VP for Medical Affairs at Novo Nordisk in Princeton.

Martin graduated from Manchester University with degrees in physiology and medicine. He also holds an MBA from Warwick University and is an adjunct professor at the Scandinavian International Management Institute.

Graham Boulnois

Professor Graham Boulnois joined SV Life Sciences as a Venture Partner in 2001 and became a Partner in 2004. Before this, he was Senior Vice President R&D at Aventis Pharma where he had global responsibility for lead generation. Prior to joining Aventis, Graham was at Zeneca Pharmaceuticals as Senior VP, Discovery Research and then with AstraZeneca Pharmaceuticals as Global VP, Enabling Science and Technology.

Before joining the pharmaceutical industry, he was Professor of Microbiology, Chairman of Biological Sciences and Pro-Dean of the Science Faculty at Leicester University.

In addition to Vantia Therapeutics, Graham is a Director of Delenex Therapeutics AG, Oxagen Ltd and Affinium Pharmaceuticals Inc.

Andy Crockett, CEO

Andy joined Vantia in 2009 from the US specialty pharma company Zars Pharma where he was most recently VP Business Development. During his career he has identified, negotiated and executed strategic corporate transactions on a global basis, including merger and acquisitions, national and international product licences, IP and technology licences, and R&D alliances.

Andrew has studied at Harvard Business School and also holds an MBA from The Wharton School, University of Pennsylvania, with a major in Finance.

Martin Murphy

Martin joined MVM Life Science Partners in 2002. He was previously a member of the healthcare investment team at 3i. Prior to that, he was an Engagement Manager with McKinsey & Company based in London and Mumbai. Martin has a degree in Biochemistry from Oxford University and completed a PhD in Molecular Biology at Cambridge University before going on to postdoctoral work in Paris.

Martin is also a member of the boards of Heptares Therapeutics Ltd and Pulmagen Therapeutics Ltd. He was previously a director of Healthcare Brands International Ltd and PregLem SA.

Hamish Cameron

Dr Hamish Cameron was formerly CEO at Cambridge Antibody Technology.

David McGibney

Dr David McGibney was formerly Head of R&D at Pfizer.